JAK1 Inhibitor ARQ-255 Suspension

ARQ-255 is a formulation of ARQ-252 modified to deliver the drug deep into the dermis that is being investigated for the treatment of alopecia areata.

Topical JAK1 Inhibitor Suspension (ARQ-255) in Alopecia Areata

Landscape1,2

  • There are no approved therapies for alopecia areata
  • Because of unpredictable and spontaneous remission, optimal duration of therapy and therapeutic dosing regimens have not been well characterized

Mechanism

  • Inhibition of the Janus kinase–signal transducer and activator of transcription (JAK-STAT) pathway is a promising target for the treatment of alopecia areata3
  • ARQ-255 is a selective, highly potent, topical, small-molecule JAK1 inhibitor formulated to deliver drug deep into the dermis that is being investigated for the treatment of alopecia areata
Head with missing patches of hair from alopecia areata.

Development

  • Currently in preclinical development

References

1. Wagner. J Invest Derm Symp Proc. 2015;17:67-69. 2. Fricke and Miteva. Clin Cosmet Investig Dermatol. 2015;8:397-403. 3. Triyangkulsri and Suchonwanit. Drug Des Devel Ther. 2018;12:2323-2335.

null

The information contained in this website has been developed by Arcutis Medical Affairs and is intended for healthcare professionals (HCPs) only.



You are now leaving the Arcutis medical affairs website. Arcutis Biotherapeutics is not responsible for the content of linked sites.



Doximity social icon.
Doximity social icon.